DGPharma

DGPharma has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €300,586 and a net result of €158,798. Equity is growing by ~13.3% per year across the filed fiscal years. Its solvency ranks better than 34% of 12396 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).